Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.

<h4>Background</h4>Disease-linked missense mutations can alter a protein's function with fatal consequences for the affected individual. How a single amino acid substitution in a protein affects its properties, is difficult to study in the context of the cellular proteome, because m...

Full description

Saved in:
Bibliographic Details
Main Authors: Marko Roblek, Stefan Schüchner, Veronika Huber, Katrin Ollram, Sylvia Vlcek-Vesely, Roland Foisner, Manfed Wehnert, Egon Ogris
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-05-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0010604&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850236450493169664
author Marko Roblek
Stefan Schüchner
Veronika Huber
Katrin Ollram
Sylvia Vlcek-Vesely
Roland Foisner
Manfed Wehnert
Egon Ogris
author_facet Marko Roblek
Stefan Schüchner
Veronika Huber
Katrin Ollram
Sylvia Vlcek-Vesely
Roland Foisner
Manfed Wehnert
Egon Ogris
author_sort Marko Roblek
collection DOAJ
description <h4>Background</h4>Disease-linked missense mutations can alter a protein's function with fatal consequences for the affected individual. How a single amino acid substitution in a protein affects its properties, is difficult to study in the context of the cellular proteome, because mutant proteins can often not be traced in cells due to the lack of mutation-specific detection tools. Antibodies, however, with their exquisite epitope specificity permit the detection of single amino acid substitutions but are not available for the vast majority of disease-causing mutant proteins. One of the most frequently missense-mutated human genes is the LMNA gene coding for A-type lamins. Mutations in LMNA cause phenotypically heterogenous, mostly autosomal-dominant inherited diseases, termed laminopathies. The molecular mechanisms underlying the phenotypic heterogeneity of laminopathies, however, are not well understood. Hence, the goal of this study was the development of monoclonal antibodies specific for disease-linked point-mutant A-type lamins.<h4>Methodology/principal findings</h4>Using two different approaches of antigen presentation, namely KLH-coupled peptides and the display of a complete protein domain fused to the Hepatitis B virus capsid protein, we developed monoclonal antibodies against two disease-associated lamin A/C mutants. Both antibodies display exquisite specificity for the respective mutant proteins. We show that with the help of these novel antibodies it is now possible for the first time to study specifically the properties of the mutant proteins in primary patient cells in the background of wild-type protein.<h4>Conclusions</h4>We report here the development of two point-mutant specific antibodies against A-type lamins. While synthetic peptides may be the prime choice of antigen, our results show that a given target sequence may have to be presented in alternative ways to ensure the induction of a mutant-specific immune response. Point-mutant specific antibodies will represent valuable tools for basic and clinical research on a number of hereditary as well as acquired diseases caused by dominant missense mutations.
format Article
id doaj-art-e098ed80ff6e4b34b01d1ee891463f44
institution OA Journals
issn 1932-6203
language English
publishDate 2010-05-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-e098ed80ff6e4b34b01d1ee891463f442025-08-20T02:01:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-05-0155e1060410.1371/journal.pone.0010604Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.Marko RoblekStefan SchüchnerVeronika HuberKatrin OllramSylvia Vlcek-VeselyRoland FoisnerManfed WehnertEgon Ogris<h4>Background</h4>Disease-linked missense mutations can alter a protein's function with fatal consequences for the affected individual. How a single amino acid substitution in a protein affects its properties, is difficult to study in the context of the cellular proteome, because mutant proteins can often not be traced in cells due to the lack of mutation-specific detection tools. Antibodies, however, with their exquisite epitope specificity permit the detection of single amino acid substitutions but are not available for the vast majority of disease-causing mutant proteins. One of the most frequently missense-mutated human genes is the LMNA gene coding for A-type lamins. Mutations in LMNA cause phenotypically heterogenous, mostly autosomal-dominant inherited diseases, termed laminopathies. The molecular mechanisms underlying the phenotypic heterogeneity of laminopathies, however, are not well understood. Hence, the goal of this study was the development of monoclonal antibodies specific for disease-linked point-mutant A-type lamins.<h4>Methodology/principal findings</h4>Using two different approaches of antigen presentation, namely KLH-coupled peptides and the display of a complete protein domain fused to the Hepatitis B virus capsid protein, we developed monoclonal antibodies against two disease-associated lamin A/C mutants. Both antibodies display exquisite specificity for the respective mutant proteins. We show that with the help of these novel antibodies it is now possible for the first time to study specifically the properties of the mutant proteins in primary patient cells in the background of wild-type protein.<h4>Conclusions</h4>We report here the development of two point-mutant specific antibodies against A-type lamins. While synthetic peptides may be the prime choice of antigen, our results show that a given target sequence may have to be presented in alternative ways to ensure the induction of a mutant-specific immune response. Point-mutant specific antibodies will represent valuable tools for basic and clinical research on a number of hereditary as well as acquired diseases caused by dominant missense mutations.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0010604&type=printable
spellingShingle Marko Roblek
Stefan Schüchner
Veronika Huber
Katrin Ollram
Sylvia Vlcek-Vesely
Roland Foisner
Manfed Wehnert
Egon Ogris
Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
PLoS ONE
title Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
title_full Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
title_fullStr Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
title_full_unstemmed Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
title_short Monoclonal antibodies specific for disease-associated point-mutants: lamin A/C R453W and R482W.
title_sort monoclonal antibodies specific for disease associated point mutants lamin a c r453w and r482w
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0010604&type=printable
work_keys_str_mv AT markoroblek monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT stefanschuchner monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT veronikahuber monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT katrinollram monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT sylviavlcekvesely monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT rolandfoisner monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT manfedwehnert monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w
AT egonogris monoclonalantibodiesspecificfordiseaseassociatedpointmutantslaminacr453wandr482w